Carlo Genova

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang et al. · The Lancet Oncology · 2020 · 621 citations · Full text

Virus Epidemiology, Medicine, Covid-19 Pandemic +12

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Biagio Ricciuti, Carlo Genova, Andrea De Giglio et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 357 citations · Full text

Medicine, Immunology, Multi-institutional Analysis +8

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

Maria Giovanna Dal Bello, Rosangela Filiberti, Angela Alama et al. · Journal of Translational Medicine · 2019 · 193 citations · Full text

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 146 citations · Full text

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 132 citations · Full text